A mouse mast-cell study reveals a striking split between two engineered nanoparticles: SiO2 dampened antigen-triggered allergic activation in vitro, while mTiO2 showed cytotoxic and pro-inflammatory effects.
Study: Examining the immunomodulatory role of nanoparticles on mast cell activation. Image Credit: Corona Borealis Studio / Shutterstock
In a recent study published in the journal Scientific Reports, researchers investigated how the physicochemical properties of engineered nanoparticles may impact mast cell activation relevant to cutaneous hypersensitivity reactions. The study evaluated the impact of negatively charged silica (SiO2) and manganese-doped titanium dioxide (mTiO2) nanoparticles on bone marrow-derived mast cells (BMMCs).
Study findings revealed that while mTiO2 NPs exhibited pronounced cytotoxicity and pro-inflammatory effects, SiO2 NPs protected against antigen-induced mast cell activation in vitro. In the presence of a target antigen, SiO2 significantly suppressed mast cell degranulation and the expression of activation markers, thereby providing mechanistic insights into how selected nanoparticles may modulate allergic immune responses.
Contact Dermatitis and Nanomaterial Context
Contact dermatitis is a prevalent inflammatory skin disease, with current reports estimating that the condition affects up to 9.8% of the population and accounts for approximately 90% of occupational skin disorders in the industrialized world. Furthermore, these reports highlight that the clinical incidence of allergic contact dermatitis is rising, with 17 new allergens reported annually (2008 to 2015).
Unlike the more common Irritant Contact Dermatitis (ICD), Allergic Contact Dermatitis (ACD) is a delayed-type hypersensitivity reaction initiated when a compromised epidermal (skin) barrier permits the penetration of exogenous hapten sensitizers (e.g., nickel or latex).
Encouragingly, recent advances in engineered nanomaterials have led to in vivo studies showing that small (<200 nm), negatively charged nanoparticles (NPs) can modulate the adaptive immune response. This literature used a dinitrofluorobenzene mouse model of contact hypersensitivity (a proxy for human ACD) and found that SiO2 NPs suppressed the allergic phenotype, whereas mTiO2 NPs exacerbated it.
While this research highlighted the potential of nanomaterials in treating allergic and dermatological conditions, the precise cellular mechanics driving this differential immunomodulation remained poorly understood.
Bone Marrow Mast Cells
The present study aimed to address this knowledge gap by focusing on the impacts of these nanomaterials on mast cells, which express high-affinity FcεRI receptors bound to immunoglobulin E (IgE) to mediate allergic cascades.
The study specifically used bone marrow-derived mast cells (BMMCs) harvested and differentiated from the bone marrow of outbred SKH hairless mice over a 4-week culture period. Only BMMCs that demonstrated a purity of > 95% based on c-kit (CD117+) and FcεRI+ expression were included in the experimental matrix.
The experimental matrix used two commercially available nanomaterials: negatively charged amorphous SiO2 NPs (average primary particle size of 21.42 nm by transmission electron microscopy [TEM]) and negatively charged 1% mTiO2 NPs (56.02 nm).
The experimental procedure comprised first sensitizing BMMCs using 1 μg/mL anti-dinitrophenyl (anti-DNP) IgE. The sensitized cells were subsequently exposed to NPs alone or co-incubated with 100 ng/mL DNP-human serum albumin antigen to crosslink the FcεRI receptors and model antigen-mediated mast cell activation.
Key endpoints were measured using flow cytometry (for cell viability estimates), β-hexosaminidase release assays (for degranulation quantification), and cytokine secretion profiles (IL-6, IL-13, and TNF-α measured via enzyme-linked immunosorbent assay [ELISA]).
Finally, multiparametric flow cytometry was used to measure the median fluorescence intensity (MFI) of specific cell-surface markers for activation and degranulation, including FcεRI, CD117, CD63, and CD107a.
SiO2 and mTiO2 Produce Opposite Effects
The study’s cytotoxicity profile estimates established that mTiO2 induces significant dose- and time-dependent cell death. Brief 1-hour exposure to concentrations >25 μg/mL was found to be sufficient to cause a >30% reduction in BMMC viability.
In contrast, SiO2 exhibited remarkable biocompatibility, maintaining 90% cell viability even after a 24-hour incubation (at 100 μg/mL). TEM images confirmed that mTiO2 NPs (1 μg/mL) were actively endocytosed within 30 minutes, whereas no structural evidence of uptake was observed for SiO2 (10 μg/mL).
In the absence of an antigen, mTiO2 acted as a cytotoxic and pro-inflammatory stressor, causing baseline degranulation at 25 μg/mL and upregulating TNF-α production after 24 hours. Conversely, under allergen-stimulated conditions, SiO2 exerted a powerful, dose-dependent immunosuppressive effect.
Furthermore, SiO2 reduced DNP-induced IL-13 release after 24 hours. In contrast, mTiO2 exerted a pro-inflammatory effect, significantly amplifying DNP-induced IL-6 release at both 4 and 24 hours.
Phenotypic surface analysis validated these findings: DNP alone induced expected activation kinetics by downregulating FcεRI and CD117 while upregulating the lysosome-associated membrane proteins (CD63 and CD107a).
Co-exposure with SiO2 was shown to successfully halt the downregulation of FcεRI and markedly diminish the surface expression spikes of CD63 and CD107a. In contrast, co-exposure with mTiO2 did not substantially alter DNP-driven FcεRI, CD117, or CD107a responses and slightly downregulated CD63.
Nanotherapy Potential For Allergic Disease
This study confirms that nanoparticles can modulate early mast cell responses involving high-affinity IgE receptor pathways, although non-IgE mechanisms cannot be excluded. While mTiO2 acts as an environmental stressor with cytotoxic and pro-inflammatory effects, SiO2 behaves as a potent in vitro suppressor of antigen-induced mast cell activation.
Though limited to an in vitro model, these findings provide a mechanistic framework for evaluating unknown compounds. Ultimately, this research may inform the design of future nanotherapies against allergic conditions.
Download your PDF copy by clicking here.
New nanoparticles disable drug resistance to achieve complete tumor elimination